Importance of Influenza Anti-Hemagglutinin Antibodies During the SARS-CoV-2 Pandemic in the 2019/2020 Epidemic Season in Poland

Lidia B. Brydak; Karol Szymański; Katarzyna Kondratiuk; Anna Poznańska; Adam Kolondra; Ewelina Hallmann

doi:10.12659/MSM.936495

20 May 2022 : Clinical Research

Importance of Influenza Anti-Hemagglutinin Antibodies During the SARS-CoV-2 Pandemic in the 2019/2020 Epidemic Season in Poland

Lidia B. Brydak^1ADEFG, Karol Szymański^1BF, Katarzyna Kondratiuk^1BF, Anna Poznańska^2CDE, Adam Kolondra^1B, Ewelina Hallmann^1BDEF*

DOI: 10.12659/MSM.936495

Med Sci Monit 2022; 28:e936495

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 4 Comparison of parameters of 300 people aged 15–64 years from the 2019/2020 serological review (3 combined age groups) with those of COVID convalescents (934 people).

	2019/2020 (age 15–64)		COVID convalescents		p
	N	Value	N	Value	p

Response rate	300	32.7 [27.4–38.0]%	934	37.8 [34.7–40.9]%	NS
GMT	98	69.0 [58.4–79.5]	353	99.7 [90.6–108.7]

Response rate	300	60.7 [55.1–66.2]%	934	63.8 [60.7–66.9]%	NS
GMT	182	89.0 [81.0–97.0]	596	98.2 [92.7–103.6]	NS

Response rate	300	4.3 [2.0–6.6]%	934	32.3 [29.3–35.3]%
GMT	13	52.2 [38.4–66.1]	302	80.7 [74.1–87.3]

Response rate	300	31.7 [26.4–36.9]%	934	61.6 [58.4–64.7]%
GMT	95	76.0 [66.5–85.5]	575	76.4 [72.1–80.7]	NS

Back to the Article

Importance of Influenza Anti-Hemagglutinin Antibodies During the SARS-CoV-2 Pandemic in the 2019/2020 Epidemic Season in Poland

Your Privacy